Radiotherapy for Benign Disease: Current Evidence, Benefits and Risks
Roger Taylor(Swansea University), Richard Shaffer(Bupa Cromwell Hospital), Paul Hatfield(St James's University Hospital), S. R. McKeown(University of Ulster), Robin Prestwich
Cited by 20
Related Papers
Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2008|532
Volumetric Modulated Arc Therapy Improves Dosimetry and Reduces Treatment Time Compared to Conventional Intensity-Modulated Radiotherapy for Locoregional Radiotherapy of Left-Sided Breast Cancer and Internal Mammary Nodes
|International Journal of Radiation Oncology*Biology*Physics|2009|365
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
|Annals of Oncology|2018|252
A Comparison of Volumetric Modulated Arc Therapy and Conventional Intensity-Modulated Radiotherapy for Frontal and Temporal High-Grade Gliomas
|International Journal of Radiation Oncology*Biology*Physics|2009|153
Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation
|British Journal of Radiology|2015|117